Abbott on Bioeconhttps://en.bioecon.ru/companies/abbott/Recent content in Abbott on BioeconHugoen-USMon, 20 Jul 2026 15:05:48 +0700Point-of-care molecular diagnosticshttps://en.bioecon.ru/technology/point-of-care-molecular-diagnostics/Mon, 20 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/point-of-care-molecular-diagnostics/Lab-free, sample-to-answer molecular testing platforms delivering PCR-grade results at the bedside, clinic or field site in minutes rather than the hours a central lab requires: Cepheid’s GeneXpert (Danaher) and bioMérieux’s BIOFIRE cartridge-based systems, Abbott’s ID NOW isothermal platform, Sansure Biotech’s domestic POCT scale-up in China, and Molbio Diagnostics’ Truenat chip-based platform serving resource-limited settings from India.Wearable biodiagnosticshttps://en.bioecon.ru/technology/wearable-biodiagnostics/Thu, 25 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/wearable-biodiagnostics/Wearable biodiagnostics and continuous monitoring systems enabling real-time precision health management.Diagnostics & biosensorshttps://en.bioecon.ru/technology/diagnostics-biosensors/Wed, 24 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/diagnostics-biosensors/Advanced analytical devices detecting biological markers to enable rapid, precise disease identification and monitoring.